Holen Sie sich die Stockscreener-App
2.02
4.12%
0.08
Handel nachbörslich:
2.02
Kiora Pharmaceuticals Inc Aktie (KPRX) Neueste Nachrichten
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan
Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan
KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Kiora Pharmaceuticals Inc outperform its industry peersProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Should I hold or sell Kiora Pharmaceuticals Inc nowQuarterly Market Review & Accurate Trade Setup Notifications - baoquankhu1.vn
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
Two retinal disease trials underway as Kiora says cash lasts into 2027 - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
Sectors Review: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
KPRX Should I Buy - Intellectia AI
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards - Stock Titan
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding - Stock Titan
Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Fear: Can Kiora Pharmaceuticals Inc keep up with sector leadersRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Retail Trends: Is Kiora Pharmaceuticals Inc a defensive stockWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
What is Kiora Pharmaceuticals Inc. s debt to equity ratioIPO Watch & Community Verified Swing Trade Signals - mfd.ru
SEC EDGAR Submission 0001104659-22-079906 - SEC.gov
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
KPRX Technical Analysis & Stock Price Forecast - Intellectia AI
KPRX PE Ratio & Valuation, Is KPRX Overvalued - Intellectia AI
Can Kiora Pharmaceuticals Inc. stock hit record highs againMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru
Weekly Earnings: Whats the profit margin of Kiora Pharmaceuticals IncJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Comparing Kiora Pharmaceuticals (NASDAQ:KPRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) - Defense World
Quarterly Earnings: Can MicroSectors Gold Miners 3X Leveraged ETNs due June 29 2040 continue delivering strong returnsTrend Reversal & Target Return Focused Picks - baoquankhu1.vn
Volatility Watch: Is Kiora Pharmaceuticals Inc a defensive stockBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Fund Flows: Is Kiora Pharmaceuticals Inc stock supported by innovation pipeline2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - Bộ Nội Vụ
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - Улправда
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - Улправда
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):